<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>å°ç£èˆ‡åœ‹éš›ç½•è¦‹ç–¾ç—…ï¼å­¤å…’è—¥åˆ¶åº¦æ¯”è¼ƒ</title>
    <meta name="description" content="å°ç£ã€æ­ç¾ã€æ—¥ã€åŠ ã€æ¾³ç½•è¦‹ç–¾ç—…èˆ‡å­¤å…’è—¥åˆ¶åº¦æœ€æ–°æ¯”è¼ƒï¼šå®šç¾©ã€æ¿€å‹µã€æ³•æºã€çµ¦ä»˜èˆ‡æ”¿ç­–æ¶æ§‹ã€‚">
    <meta data-version="1.2" data-last-updated="2025-09-09">
    <style>
        :root {
            --c-primary:#2563eb;
            --c-secondary:#0d6efd;
            --c-bg:#f5f7fa;
            --c-border:#e2e8f0;
            --c-danger:#dc3545;
            --c-warn:#f59e0b;
            --c-ok:#059669;
            --c-info:#0ea5e9;
            --c-muted:#64748b;
            --c-highlight:#fff8e1;
            --radius:10px;
        }
        body {
            font-family:"Microsoft JhengHei",Arial,sans-serif;
            margin:0;
            padding:20px;
            background:var(--c-bg);
            line-height:1.65;
            color:#1e293b;
        }
        .container {
            max-width:1450px;
            margin:0 auto;
            background:#fff;
            padding:32px 40px 60px;
            border-radius:var(--radius);
            box-shadow:0 6px 28px -8px rgba(0,0,0,.12);
            position:relative;
        }
        h1 {
            margin:0 0 28px;
            text-align:center;
            font-size:2.25rem;
            background:linear-gradient(135deg,var(--c-primary),#0ea5e9);
            -webkit-background-clip:text;
            color:transparent;
            letter-spacing:.5px;
        }
        .meta-bar {
            display:flex;
            flex-wrap:wrap;
            gap:16px;
            font-size:.85rem;
            background:#eff6ff;
            border:1px solid #bfdbfe;
            padding:10px 16px;
            border-radius:var(--radius);
            margin-bottom:25px;
        }
        .badge {
            display:inline-block;
            padding:3px 10px 4px;
            font-size:.7rem;
            letter-spacing:.5px;
            border-radius:999px;
            background:#1d4ed8;
            color:#fff;
            margin-right:6px;
            vertical-align:middle;
        }
        .toc {
            background:#f1f5f9;
            border:1px solid var(--c-border);
            padding:22px 26px;
            border-radius:var(--radius);
            margin-bottom:38px;
            position:relative;
        }
        .toc h2 {
            margin:0 0 14px;
            font-size:1.25rem;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
        }
        .toc ul {
            list-style:none;
            padding:0;
            margin:0;
            columns:2;
        }
        .toc li {
            margin:6px 0;
            break-inside:avoid;
        }
        .toc a {
            text-decoration:none;
            color:var(--c-secondary);
            font-weight:500;
            position:relative;
            padding-left:4px;
        }
        .toc a:hover {
            text-decoration:underline;
            color:#1d4ed8;
        }
        .law-section {
            border:1px solid var(--c-border);
            border-radius:var(--radius);
            margin-bottom:55px;
            overflow:hidden;
            background:#ffffff;
        }
        .law-header {
            margin:0;
            padding:18px 24px;
            background:linear-gradient(120deg,#1e3a8a,#1d4ed8 50%,#2563eb);
            color:#fff;
            font-size:1.45rem;
            letter-spacing:.5px;
            display:flex;
            justify-content:space-between;
            flex-wrap:wrap;
            gap:12px;
        }
        .law-meta {
            background:#f8fafc;
            padding:14px 22px;
            font-size:.85rem;
            border-top:1px solid var(--c-border);
            border-bottom:1px solid var(--c-border);
            color:#475569;
            line-height:1.5;
        }
        .law-content {
            padding:30px 34px 40px;
        }
        .article {
            margin-bottom:32px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            border-left:5px solid var(--c-primary);
            border-radius:6px;
            padding:18px 22px 20px;
            position:relative;
        }
        .article-title {
            font-weight:600;
            font-size:1.05rem;
            margin:0 0 14px;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
            flex-wrap:wrap;
        }
        .article-title .small-label {
            background:#e0f2fe;
            color:#0369a1;
            font-size:.6rem;
            padding:2px 6px 3px;
            border-radius:4px;
            letter-spacing:.5px;
        }
        .bilingual-content {
            display:grid;
            grid-template-columns:1fr 1fr;
            gap:20px;
        }
        .original-text, .translation {
            padding:14px 16px 16px;
            border-radius:8px;
            font-size:.9rem;
            position:relative;
            line-height:1.55;
        }
        .original-text {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
        }
        .translation {
            background:#fffceb;
            border:1px solid #fde68a;
        }
        .lang-label {
            font-size:.62rem;
            font-weight:600;
            letter-spacing:.8px;
            color:#334155;
            background:#e2e8f0;
            padding:4px 8px;
            border-radius:999px;
            display:inline-block;
            margin-bottom:10px;
        }
        .highlight-box {
            background:#eef6ff;
            padding:18px 22px;
            border-left:6px solid #2563eb;
            border-radius:8px;
            margin:30px 0 10px;
            font-size:.92rem;
        }
        .highlight-box h3 {
            margin:0 0 14px;
            font-size:1rem;
            color:#1e3a8a;
            letter-spacing:.5px;
        }
        .point-list {
            margin:0;
            padding:0;
            list-style:none;
            display:grid;
            gap:10px;
        }
        .point-item {
            position:relative;
            padding-left:18px;
            font-size:.9rem;
        }
        .point-item:before {
            content:"â—†";
            font-size:.55rem;
            color:#2563eb;
            position:absolute;
            left:0;
            top:5px;
        }
        .comparison-wrapper {
            overflow-x:auto;
            margin-top:10px;
        }
        table.comparison-table {
            width:100%;
            border-collapse:collapse;
            font-size:.82rem;
            min-width:1150px;
        }
        .comparison-table th, .comparison-table td {
            border:1px solid #e2e8f0;
            padding:9px 9px;
            text-align:left;
            vertical-align:top;
        }
        .comparison-table th {
            background:#1e3a8a;
            color:#ffffff;
            position:sticky;
            top:0;
            z-index:2;
            font-weight:600;
            letter-spacing:.5px;
        }
        .comparison-table tbody tr:nth-child(even) {
            background:#f8fafc;
        }
        .comparison-table td .note-inline {
            display:block;
            font-size:.65rem;
            color:#64748b;
            margin-top:4px;
            line-height:1.25;
        }
        .footnotes {
            background:#f8fafc;
            border:1px solid var(--c-border);
            padding:24px 28px 30px;
            border-radius:var(--radius);
            font-size:.75rem;
            line-height:1.45;
            margin-top:60px;
        }
        .footnotes h3 {
            margin:0 0 14px;
            font-size:.92rem;
            color:#0f172a;
        }
        .footnotes ol { margin:0; padding-left:18px; }
        .footnotes li { margin:6px 0; }
        .callout {
            border:1px solid #cbd5e1;
            background:#ffffff;
            padding:16px 18px;
            border-radius:8px;
            margin:24px 0;
            display:flex;
            gap:14px;
            font-size:.85rem;
            position:relative;
        }
        .callout.info { border-color:#93c5fd; background:#eff6ff; }
        .callout.warn { border-color:#fcd34d; background:#fffbeb; }
        .callout.danger { border-color:#fca5a5; background:#fef2f2; }
        .callout strong { color:#0f172a; }
        .legend {
            display:flex;
            flex-wrap:wrap;
            gap:10px;
            margin:14px 0 4px;
            font-size:.62rem;
        }
        .legend span {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            padding:4px 8px;
            border-radius:6px;
            display:flex;
            align-items:center;
            gap:4px;
        }
        .legend code {
            background:#e2e8f0;
            padding:2px 4px;
            border-radius:4px;
            font-size:.6rem;
        }
        .revision-log {
            margin-top:55px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            padding:20px 24px 26px;
            border-radius:var(--radius);
            font-size:.8rem;
        }
        .revision-log h3 {
            margin:0 0 12px;
            font-size:.95rem;
        }
        .revision-log ul {
            margin:0;
            padding-left:18px;
            line-height:1.5;
        }
        .source-links {
            display:grid;
            gap:14px;
            grid-template-columns:repeat(auto-fill,minmax(260px,1fr));
            margin-top:14px;
        }
        .source-card {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            border-radius:8px;
            padding:12px 14px 14px;
            font-size:.68rem;
            line-height:1.35;
            position:relative;
        }
        .source-card h4 {
            margin:0 0 6px;
            font-size:.72rem;
            color:#0f172a;
        }
        .source-card a {
            word-break:break-all;
            color:#1d4ed8;
            text-decoration:none;
        }
        .source-card a:hover { text-decoration:underline; }
        .disclaimer {
            margin-top:60px;
            padding:20px 24px;
            background:#fef2f2;
            border:1px solid #fecaca;
            border-radius:var(--radius);
            font-size:.74rem;
            line-height:1.5;
            color:#991b1b;
        }
        .back-to-top {
            position:fixed;
            right:26px;
            bottom:26px;
            width:50px;
            height:50px;
            background:#2563eb;
            color:#fff;
            border:none;
            border-radius:50%;
            cursor:pointer;
            font-size:18px;
            display:none;
            box-shadow:0 4px 16px -4px rgba(0,0,0,.35);
            transition:.25s;
        }
        .back-to-top:hover { background:#1d4ed8; transform:translateY(-3px); }
        mark {
            background:#fde68a;
            padding:1px 3px;
            border-radius:4px;
        }
        .label {
            display:inline-block;
            font-size:.55rem;
            padding:3px 6px;
            background:#e2e8f0;
            color:#334155;
            border-radius:4px;
            letter-spacing:.5px;
            margin-left:6px;
        }
        @media (max-width:980px){
            .bilingual-content { grid-template-columns:1fr; }
            .toc ul { columns:1; }
            .law-content { padding:26px 22px 30px; }
            .article { padding:16px 16px 18px; }
            h1 { font-size:1.9rem; }
        }
        @media (max-width:600px){
            body { padding:12px; }
            .container { padding:22px 20px 50px; }
            .law-header { font-size:1.15rem; }
        }
    </style>
</head>
<body>
  <div class="container">
    <h1>ğŸŒ å°ç£å„ªå…ˆè¦–è§’ï¼šåœ‹éš›ç½•è¦‹ç–¾ç—…ï¼å­¤å…’è—¥åˆ¶åº¦æ¯”è¼ƒï¼ˆä¿®è¨‚å¢è£œç‰ˆï¼‰</h1>

    <div class="meta-bar">
      <div><span class="badge">VERSION</span> 1.2ï¼ˆå¢è£œå°ç£å„ªå…ˆï¼‰</div>
      <div><span class="badge" style="background:#059669;">æ›´æ–°æ—¥æœŸ</span> 2025-09-09</div>
      <div><span class="badge" style="background:#0ea5e9;">æ¶µè“‹</span> å°ç£ / ç¾åœ‹ / æ­ç›Ÿ / æ—¥æœ¬ / åŠ æ‹¿å¤§ / æ¾³æ´²</div>
      <div><span class="badge" style="background:#9333ea;">èªè¨€</span> ä¸­æ–‡ç‚ºä¸» + é—œéµè‹±æ–‡æ‘˜è¦</div>
    </div>

    <div class="callout info">
      <div><strong>èªªæ˜ï¼š</strong>æœ¬ç‰ˆä¾æ‚¨è¦æ±‚ã€Œå°ç£ç½®é ‚ã€ï¼Œå…¨é¢æ•´åˆæœ€æ–°å¯å…¬é–‹è³‡è¨Šï¼Œä¸¦å°ã€Œå®šç¾©å·®ç•°ã€æ¿€å‹µå·¥å…·å±¬æ€§ã€çµ¦ä»˜ç‰¹å¾µã€é€²è¡Œçµæ§‹åŒ–å‘ˆç¾ï¼›å·²æ’é™¤å…ˆå‰éæ™‚æ•˜è¿°ï¼Œä¸¦æ¨™è¨»æ”¿ç­–æ€§ vs æ³•å®šæ€§å·®ç•°ã€‚è‹¥å°‡ç”¨æ–¼æ­£å¼æ”¿ç­–å ±å‘Šï¼Œå»ºè­°å†è¡Œå…§éƒ¨æ³•å‹™è¤‡æ ¸ã€‚</div>
    </div>

    <div class="legend">
      <span><code>æ³•å®š</code> = æ³•æ¢æ˜è¨‚</span>
      <span><code>æ”¿ç­–</code> = è¡Œæ”¿/å¯¦å‹™é‹ä½œ</span>
      <span><code>è§€å¯Ÿ</code> = åˆ†ææ€§è£œè¿°</span>
    </div>

    <div class="toc">
      <h2>ğŸ“‹ ç›®éŒ„</h2>
      <ul>
        <li><a href="#taiwan-rare-disease-act">ä¸€ã€å°ç£ç½•è¦‹ç–¾ç—…é˜²æ²»åŠè—¥ç‰©åˆ¶åº¦</a></li>
        <li><a href="#usa-orphan-drug-act">äºŒã€ç¾åœ‹å­¤å…’è—¥æ³• (Orphan Drug Act)</a></li>
        <li><a href="#eu-orphan-regulation">ä¸‰ã€æ­ç›Ÿå­¤å…’è—¥è¦å‰‡ (Reg. 141/2000)</a></li>
        <li><a href="#japan-intractable-disease-act">å››ã€æ—¥æœ¬ã€Šé›£ç—…æ³•ã€‹èˆ‡æŒ‡å®šé›£ç—…</a></li>
        <li><a href="#canada-rare-strategy">äº”ã€åŠ æ‹¿å¤§ç½•è¦‹ç–¾ç—…ç­–ç•¥</a></li>
        <li><a href="#australia-orphan-program">å…­ã€æ¾³æ´² TGA å­¤å…’è—¥åˆ¶åº¦</a></li>
        <li><a href="#comparison-table">ä¸ƒã€æ¯”è¼ƒç¸½è¡¨</a></li>
        <li><a href="#sources">å…«ã€ä¾†æºèˆ‡åƒè€ƒ</a></li>
        <li><a href="#revision-log">ä¹ã€ä¿®è¨‚ç´€éŒ„</a></li>
        <li><a href="#disclaimer">åã€å…è²¬è²æ˜</a></li>
      </ul>
    </div>

    <!-- TAIWAN -->
    <section id="taiwan-rare-disease-act" class="law-section">
      <h2 class="law-header">ä¸€ã€å°ç£ ç½•è¦‹ç–¾ç—…é˜²æ²»åŠè—¥ç‰©åˆ¶åº¦ï¼ˆRare Disease Prevention and Orphan Drugs Actï¼‰</h2>
      <div class="law-meta">
        åˆè¨‚ï¼š2000 å¹´ | ä¸»ç®¡æ©Ÿé—œï¼šè¡›ç”Ÿç¦åˆ©éƒ¨ï¼ˆMOHWï¼‰ | ç›¸é—œæ³•æºï¼šç½•è¦‹ç–¾ç—…é˜²æ²»åŠè—¥ç‰©æ³•ã€å…¨æ°‘å¥åº·ä¿éšªæ³•ã€ç”¢æ¥­å‰µæ–°æ¢ä¾‹ã€è—¥äº‹æ³•ã€è¸å“å¥åº·ç¦åˆ©ææ¢ä¾‹
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">ï¼ˆ1ï¼‰å®šç¾©èˆ‡æŒ‡å®šæ©Ÿåˆ¶ <span class="small-label">æ³•å®š + è¡Œæ”¿æº–å‰‡</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">ä¸­æ–‡ï¼ˆå¯¦å‹™æ‘˜è¦ï¼‰</div>
              ç½•è¦‹ç–¾ç—…ä¹‹èªå®šä¾æ³•ç¬¬ 3 æ¢æˆæ¬Šä¸­å¤®ä¸»ç®¡æ©Ÿé—œè¨‚å®šæ¨™æº–ï¼›ç¾è¡Œè¡Œæ”¿åŸºæº–æ¡ã€Œåœ‹å…§ç››è¡Œç‡ â‰¤ 1/10,000ã€ä¸¦è€ƒé‡ï¼šç–¾ç—…åš´é‡æ€§ã€è¨ºæ–·å›°é›£åº¦ã€æ²»ç™‚å¯è¿‘æ€§ã€æ˜¯å¦ç¼ºä¹æ›¿ä»£ç™‚æ³•ã€‚<br><br>
              æŒ‡å®šç¨‹åºï¼šç–¾ç—…è³‡æ–™å½™æ•´ â†’ ç”³è«‹/å¯©è­°ï¼ˆå°ˆå®¶å¯©æŸ¥æœƒï¼‰â†’ å…¬å‘Šåˆ—å…¥ç½•è¦‹ç–¾ç—…æ¸…å–® â†’ ç›¸å°æ‡‰è—¥ç‰©å¾—ç”³è«‹ç‚ºã€Œç½•è¦‹ç–¾ç—…ç”¨è—¥ã€ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Taiwan defines a rare disease administratively as a condition with domestic prevalence â‰¤1/10,000 plus qualitative criteria (severity, diagnostic difficulty, lack of effective therapy). Designation involves expert review and official listing; orphan drugs for listed diseases may access specific funding and reimbursement pathways.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">ï¼ˆ2ï¼‰æ³•å®šæ”¯æŒèˆ‡è²¡æºæ¶æ§‹ <span class="small-label">æ³•å®š / æ”¿ç­–</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">ä¸­æ–‡</div>
              1. å°ˆæ¬¾åŸºé‡‘ï¼šè¨­ç½®ã€Œç½•è¦‹ç–¾ç—…é˜²æ²»åŸºé‡‘ã€æ”¯æ‡‰ç ”ç©¶ã€æ•™è‚²ã€æ‚£è€…æ”¯æŒï¼ˆæ³•å®šä¾†æºï¼šæ”¿åºœé ç®—ã€æè´ˆã€åˆ©æ¯ç­‰ï¼‰ã€‚<br>
              2. é†«ç™‚çµ¦ä»˜ï¼šå¥ä¿å°å¤šæ•¸ç½•è¦‹ç–¾ç—…è—¥å“æ¡è«‹é ˜å¯©æŸ¥åˆ¶ï¼Œæ ¸å‡†å¾Œç”±å¥ä¿æ”¯æ‡‰ï¼Œé«˜é¡æ–°è—¥å¸¸ä»¥ã€Œå°ˆæ¡ˆæ”¯ä»˜ã€æˆ–ã€Œé¢¨éšªåˆ†æ”¤ã€æ¨¡å¼ã€‚<br>
              3. è²¡å‹™ä¾†æºè£œå¼·ï¼šè¸å“å¥åº·ç¦åˆ©ææŒ¹æ³¨å…¬å…±è¡›ç”Ÿæ”¯å‡ºï¼ˆé–“æ¥æ”¯æŒç½•ç—…è³‡æºé…ç½®ï¼‰ã€‚<br>
              4. è‡ªä»˜æ¸›å…ï¼šå°ç¬¦åˆæ¢ä»¶ç½•ç—…æ‚£è€…ä¹‹é†«ç™‚è²»ç”¨éƒ¨åˆ†æˆ–å…¨éƒ¨æ¸›å…ã€‚<br>
              5. ç”¢æ¥­èª˜å› ï¼šå¯ä½µç”¨ã€Œç”¢æ¥­å‰µæ–°æ¢ä¾‹ã€ç ”ç™¼æŠ•æŠµèˆ‡è—¥äº‹æ³•ä¸‹å¿«é€Ÿå¯©æŸ¥æ©Ÿåˆ¶ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Funding pillars: (a) dedicated rare disease fund (government + donations), (b) National Health Insurance (NHI) reimbursement with prior review, (c) public health surcharges (tobacco) supporting broader allocation, (d) out-of-pocket relief, (e) R&D tax incentives via general innovation statute, (f) managed entry / riskâ€‘sharing for high-cost therapies.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">ï¼ˆ3ï¼‰è—¥ç‰©å¯©æŸ¥èˆ‡çµ¦ä»˜æµç¨‹ <span class="small-label">æµç¨‹æ‘˜è¦</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">ä¸­æ–‡</div>
              (A) è—¥è­‰ï¼šè‹¥åœ‹éš›å·²ä¸Šå¸‚ï¼Œæäº¤å¢ƒå¤–è‡¨åºŠè³‡æ–™ + å“è³ªæ–‡ä»¶ï¼›å¿…è¦æ™‚å¾—åŠ é€Ÿæˆ–ç°¡åŒ–å¯©æŸ¥ã€‚<br>
              (B) çµ¦ä»˜ï¼šæäº¤è—¥ç‰©ç¶“æ¿Ÿè©•ä¼°ï¼ˆå…·æŒ‘æˆ°æ€§å› ç—…æ‚£å°‘ï¼‰ï¼Œæ¡ã€Œè‡¨åºŠå¿…è¦æ€§ + æ›¿ä»£æ€§ä¸è¶³ + é ç®—å½±éŸ¿ã€ç¶œåˆåˆ¤æ–·ã€‚<br>
              (C) å¸¸è¦‹æ¨¡å¼ï¼šè³‡æ–™é™åˆ¶ â†’ æ¡æ¢ä»¶å¼çµ¦ä»˜ï¼ˆå«ç™‚æ•ˆå†è©•ä¼°ç¯€é»ï¼‰ã€‚<br>
              (D) é¢¨éšªåˆ†æ”¤ï¼šæˆæœå°å‘ (Outcome-based) æˆ–æ”¯å‡ºä¸Šé™ (Cap) å½¢å¼é€æ­¥å¢åŠ ã€‚<br>
              (E) å¯¦è­‰è£œå¼·ï¼šé¼“å‹µæ‚£è€…ç™»éŒ„ï¼ˆè¿½è¹¤ç™‚æ•ˆèˆ‡å®‰å…¨ï¼‰ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Regulatory + reimbursement path: accelerated review of foreign data; HTA applies modified standards due to limited evidence; conditional reimbursement with outcome reâ€‘assessment; evolving riskâ€‘sharing contracts; patient registries reinforce realâ€‘world evidence.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">ï¼ˆ4ï¼‰æ¿€å‹µæ©Ÿåˆ¶åˆ†é¡ <span class="small-label">è§£æ</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">ä¸­æ–‡</div>
              1. ç ”ç™¼æ”¯æŒï¼šç ”ç©¶è¨ˆç•«è£œåŠ©ï¼ˆèˆ‡ç§‘æŠ€éƒ¨/è¡›ç¦éƒ¨åˆä½œï¼‰<br>
              2. å¯©æŸ¥æ”¯æŒï¼šå°ˆæ¡ˆçª—å£ã€å¿…è¦æ™‚åŠ é€Ÿå¯©æŸ¥ï¼ˆæ”¿ç­–æ€§ï¼‰<br>
              3. è²¡å‹™ï¼šçµ¦ä»˜æ¸›å…ã€åŸºé‡‘è£œåŠ©ã€ç”¢å‰µæ¢ä¾‹ç ”ç™¼æŠµæ¸›ï¼ˆéå°ˆå±¬ç½•ç—…ï¼‰<br>
              4. è³‡æ–™ï¼šæ‚£è€…ç™»éŒ„èˆ‡è‡ªç„¶å²ç ”ç©¶ï¼ˆæå‡å¾ŒçºŒè©•åƒ¹ç²¾æº–åº¦ï¼‰<br>
              5. ç¤¾æœƒæ”¯æŒï¼šç½•ç—…åŸºé‡‘æœƒã€æ‚£è€…å”æœƒå¿ƒç†/æ³•è¦è«®è©¢<br>
              6. æ³¨æ„ï¼šèˆ‡ç¾/æ­ä¸åŒï¼Œç„¡ç¨ç«‹ã€ŒOrphan Market Exclusivityã€ï¼Œå±¬ã€Œçµ¦ä»˜ä¿è­· + å¯©æŸ¥å”åŠ©ã€æ¨¡å¼ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Incentives emphasize access and coverage rather than statutory exclusivity: research grants, expedited scientific dialogue, financial relief, registry data infrastructure, patient advocacy integration. No separate orphan exclusivity akin to US/EU.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">ï¼ˆ5ï¼‰æ²»ç†èˆ‡ç›£æ¸¬ <span class="small-label">æ”¿ç­–</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">ä¸­æ–‡</div>
              - å°ˆå®¶å¯©æŸ¥å§”å“¡æœƒï¼šå¯©ç–¾ç—…èˆ‡è—¥ç‰©ç´å…¥æ€§ã€‚<br>
              - æˆæœ¬ç›£æ¸¬ï¼šé«˜åƒ¹åŸºå› èˆ‡ç´°èƒç™‚æ³•å°å…¥å¾Œï¼Œæ¡ã€Œç—…ä¾‹æ•¸æ¨ä¼° + å¹´åº¦é ç®—å½±éŸ¿ã€æ¨¡å‹ã€‚<br>
              - å¯¦è­‰å¾ªç’°ï¼šæ”¶é›†çœŸå¯¦ä¸–ç•Œè³‡æ–™ï¼ˆRWDï¼‰é€²è¡Œå†è©•ä¼°ï¼Œå¯èƒ½èª¿æ•´çµ¦ä»˜æ¢ä»¶ã€‚<br>
              - å…¬å…±é€æ˜ï¼šå…¬å‘Šç½•ç—…æ¸…å–®ã€ç”¨è—¥å¯©æŸ¥åŸå‰‡èˆ‡è£œåŠ©è¦å®šã€‚
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Governance relies on expert panels, budget impact modeling for advanced therapies, iterative RWE-based reâ€‘assessment, and public transparency of lists and criteria.
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>å°ç£åˆ¶åº¦ç‰¹è‰²èˆ‡æŒ‘æˆ°</h3>
          <ul class="point-list">
            <li class="point-item"><strong>ç‰¹è‰²ï¼š</strong>å®šç¾©æœ€åš´æ ¼ï¼ˆâ‰¤1/10,000ï¼‰ï¼Œç¢ºä¿è³‡æºèšç„¦é«˜æœªæ»¿è¶³éœ€æ±‚æ—ç¾¤ã€‚</li>
            <li class="point-item">æ•´åˆå‹ï¼šé†«ç™‚çµ¦ä»˜ + åŸºé‡‘è£œåŠ© + ç¤¾æœƒæ”¯æŒåŒæ™‚é‹ä½œã€‚</li>
            <li class="point-item">å¯è¿‘æ€§é«˜ï¼šç½•ç—…è—¥ç‰©æ ¸å‡†å¾Œå¤šèƒ½è¿…é€Ÿç´å…¥æ”¯ä»˜ï¼ˆç›¸è¼ƒå¤šåœ‹ç­‰å¾…æœŸï¼‰ã€‚</li>
            <li class="point-item">æˆæœ¬å£“åŠ›ï¼šæ–°å‹åŸºå› /ç´°èƒç™‚æ³•å–®ä¾‹è¶…é«˜é¡ï¼Œæ¨å‡è²¡å‹™æ°¸çºŒå£“åŠ›ã€‚</li>
            <li class="point-item">è©•ä¼°æŒ‘æˆ°ï¼šè‡¨åºŠè©¦é©—è¦æ¨¡å°â†’éœ€ä¾è‡ªç„¶å²/åœ‹éš›è³‡æ–™è£œå¼·ã€‚</li>
            <li class="point-item">æœªä¾†ç„¦é»ï¼šè³‡æ–™æ•´åˆã€å‹•æ…‹æ”¯ä»˜æ¨¡å¼ï¼ˆPerformance-basedï¼‰èˆ‡å€è¾¨ã€Œæ¥µç½•ç—…ã€ï¼ˆè¶…ä½ç››è¡Œï¼‰ç­–ç•¥ã€‚</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- USA -->
    <section id="usa-orphan-drug-act" class="law-section">
      <h2 class="law-header">äºŒã€ç¾åœ‹å­¤å…’è—¥æ³• Orphan Drug Act (ODA)</h2>
      <div class="law-meta">
        åˆ¶å®šï¼š1983 å¹´ | ä¸»ç®¡ï¼šFDA OOPD | æœ€æ–°ä¸»è¦å½±éŸ¿ï¼š2017 ç¨…åˆ¶æ”¹é©èª¿æ•´ç¨…æ”¶æŠµå…æ¯”ä¾‹
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Section 526 - æŒ‡å®šæ¢ä»¶ <span class="small-label">æ‘˜è¦</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Sponsor may request designation if intended for a rare disease (<200,000 people in the US) or inability to recover development costs from US sales.
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              ç¬¦åˆï¼šâ‘  æ‚£è€…æ•¸ <20 è¬äºº æˆ– â‘¡ éŠ·å”®ä¸è¶³ä»¥å›æ”¶æˆæœ¬ï¼Œå³å¯ç”³è«‹å­¤å…’æŒ‡å®šã€‚
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">Section 527 - 7 å¹´å¸‚å ´ç¨å  <span class="small-label">æ³•å®š</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              7-year exclusivity for the same drug & same indication; exceptions for clinical superiority or supply issues.
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              ç²å­¤å…’é©æ‡‰ç—‡æ ¸å‡†å¾Œ 7 å¹´å…§ï¼ŒFDA ä¸æ ¸å‡†åŒè—¥åŒé©æ‡‰ç—‡ï¼ˆç‰¹å®šä¾‹å¤–ï¼‰ã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>ç¾åœ‹é‡é»</h3>
          <ul class="point-list">
            <li class="point-item">å®šç¾©ï¼š<200,000 äººæˆ–ç„¡æ³•å›æ”¶æˆæœ¬ï¼ˆé›™è»Œï¼‰</li>
            <li class="point-item">å¸‚å ´ç¨å ï¼š7 å¹´ï¼ˆå¯èˆ‡ Pediatric 6 å€‹æœˆ + Hatch-Waxman è³‡æ–™ä¿è­·ç–ŠåŠ ï¼‰</li>
            <li class="point-item">ç¨…æ”¶æŠµå…ï¼šåˆæ ¼è‡¨åºŠè©¦é©—æ”¯å‡ºä¸Šé™ 25%ï¼ˆTCJA å¾Œï¼‰</li>
            <li class="point-item">å…¶å®ƒï¼šUser Fee æ¸›å…ã€FDA Protocol Assistanceã€Grant Program</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- EU -->
    <section id="eu-orphan-regulation" class="law-section">
      <h2 class="law-header">ä¸‰ã€æ­ç›Ÿå­¤å…’è—¥è¦å‰‡ Regulation (EC) No 141/2000</h2>
      <div class="law-meta">
        ç”Ÿæ•ˆï¼š2000 å¹´ | ä¸»ç®¡ï¼šEMA (COMP) | å…’ç§‘å®Œæˆå¯å»¶é•·ç¨å è‡³ 12 å¹´
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Article 3 - æŒ‡å®šæ¢ä»¶ <span class="small-label">æ³•å®š</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Lifeâ€‘threatening / chronically debilitating & prevalence â‰¤5/10,000 OR insufficient return; AND no satisfactory method or significant benefit over existing.
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              ç››è¡Œç‡ â‰¤5/10,000 æˆ– ç„¡è¶³å¤ å›å ±ï¼›ä¸” ç„¡æ»¿æ„ç™‚æ³•æˆ–å…·é¡¯è‘—æ•ˆç›Šã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>æ­ç›Ÿé‡é»</h3>
          <ul class="point-list">
            <li class="point-item">å¸‚å ´ç¨å ï¼š10 å¹´ï¼ˆç¬¬ 6 å¹´èµ·å¯å› å¤±å»ã€Œé¡¯è‘—æ•ˆç›Šã€æˆ–ä¾›æ‡‰ä¸è¶³ç¸®çŸ­ï¼›å…’ç§‘å»¶ 2 å¹´ï¼‰</li>
            <li class="point-item">æ¿€å‹µï¼šé›†ä¸­å¯©è©•ã€è²»ç”¨æ¸›å…ã€Protocol Assistanceã€SME æ”¯æŒ</li>
            <li class="point-item">é¡¯è‘—æ•ˆç›Šï¼ˆSignificant Benefitï¼‰ç‚ºå¾ŒçºŒç¶­æŒæ’ä»–æ ¸å¿ƒåˆ¤æº–</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Japan -->
    <section id="japan-intractable-disease-act" class="law-section">
      <h2 class="law-header">å››ã€æ—¥æœ¬ã€Šé›£ç—…æ³•ã€‹èˆ‡æŒ‡å®šé›£ç—…åˆ¶åº¦</h2>
      <div class="law-meta">
        åˆ¶å®šï¼š2014 / æ–½è¡Œï¼š2015 | ä¸»ç®¡ï¼šåšç”ŸåŠ´åƒçœ | ç„¦é»ï¼šé†«ç™‚è²»åŠ©æˆï¼‹ç ”ç©¶ç™»éŒ„
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">æŒ‡å®šé›£ç—…ä¸»è¦è¦ç´  <span class="small-label">æ”¿ç­– + æ³•å®šæ¢ä»¶</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">æ—¥æ–‡è¦æ—¨</div>
              ç™ºç—…æ©Ÿåºä¸æ˜ã€æ²»ç™‚ç¢ºç«‹ç„¡ã€é•·æœŸç™‚é¤Šè¦ã€æ‚£è€…æ•°ä½ï¼ˆæ”¿ç­–åƒè€ƒç´„äººå£ 0.1% ä»¥ä¸‹ï¼‰ã€å®¢è¦³çš„è¨ºæ–­åŸºæº–æœ‰ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              äº”è¦ç´ ä¸¦è¡Œï¼šç—…å› æœªæ˜ã€ç„¡æ ¹æ²»ç™‚æ³•ã€éœ€é•·æœŸç™‚é¤Šã€æ‚£è€…æ•¸ä½ï¼ˆç´„äººå£ 0.1% ä»¥ä¸‹éšå±¤åƒè€ƒï¼‰ã€æœ‰å®¢è§€è¨ºæ–·æ¨™æº–ã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>æ—¥æœ¬ç‰¹è‰²</h3>
          <ul class="point-list">
            <li class="point-item">é‡é»åœ¨ã€ŒåŠ©æˆèˆ‡ç ”ç©¶ç¶²çµ¡ã€éå¸‚å ´ç¨å </li>
            <li class="point-item">è¨­æœ‰å…¨åœ‹æ‚£è€…ç™»éŒ„ä¿ƒé€²è‡ªç„¶å²èˆ‡å¯¦è­‰</li>
            <li class="point-item">æ‰€å¾—èˆ‡é‡ç—‡åˆ†é¡å½±éŸ¿é†«ç™‚è²»è£œåŠ©å±¤ç´š</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Canada -->
    <section id="canada-rare-strategy" class="law-section">
      <h2 class="law-header">äº”ã€åŠ æ‹¿å¤§ç½•è¦‹ç–¾ç—…åœ‹å®¶ç­–ç•¥</h2>
      <div class="law-meta">
        ç¾æ³ï¼šç„¡å°ˆå±¬å­¤å…’è—¥æ³• | 2023 å•Ÿå‹• National Strategy (CAD 10 å„„ / 3 å¹´)
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">åˆ¶åº¦ç‹€æ…‹ <span class="small-label">æ”¿ç­–</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">åŸèƒŒæ™¯</div>
              å…ˆå‰æ›¾æ“¬è‰æ¡ˆä½†æœªå®šæ¡ˆï¼›æ¡åœ‹éš›æ¯”è¼ƒèˆ‡å€‹æ¡ˆå¼è©•ä¼°ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              ç„¡çµ±ä¸€å®šç¾©èˆ‡æ’ä»–ï¼›æ¡ä¸€èˆ¬è—¥å“ 8 å¹´è³‡æ–™ä¿è­·ï¼ˆå…’ç§‘ +6 å€‹æœˆï¼‰è€Œéå­¤å…’å°ˆå±¬ï¼›ç­–ç•¥é‡é»ï¼šåŠ é€Ÿå¯åŠã€å”èª¿ HTAã€è³‡æ–™äº’é€šèˆ‡æ‚£è€…åƒèˆ‡ã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>åŠ æ‹¿å¤§é‡é»</h3>
          <ul class="point-list">
            <li class="point-item">ç¼ºå°ˆæ³• â†’ æ¿€å‹µç›¸å°å¼±</li>
            <li class="point-item">é€éè¯é‚¦è³‡é‡‘æ”¯æŒçœç´šå”èª¿</li>
            <li class="point-item">è³‡æ–™èˆ‡å…¬å¹³å¯åŠç‚ºæ”¿ç­–å„ªå…ˆ</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Australia -->
    <section id="australia-orphan-program" class="law-section">
      <h2 class="law-header">å…­ã€æ¾³æ´² TGA å­¤å…’è—¥åˆ¶åº¦</h2>
      <div class="law-meta">
        å‰µç«‹ï¼š1998 | 2017 æ”¹ç‰ˆ | ä¸»ç®¡ï¼šTGA | æ ¸å¿ƒï¼šè²»ç”¨æ¸›å… + æŒ‡å®š
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">æŒ‡å®šæ¢ä»¶ <span class="small-label">æ”¿ç­–æº–å‰‡</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Prevalence <5/10,000 in Australia OR not commercially viable without incentives; serious condition; no alternative with comparable benefit.
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              ç››è¡Œç‡ <5/10,000 æˆ–ç¼ºä¹å•†æ¥­å¯è¡Œæ€§ï¼›å±¬åš´é‡ç–¾ç—…ï¼›ä¸”ç„¡å…·åŒç­‰æ•ˆç›Šæ›¿ä»£ç™‚æ³•ã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>æ¾³æ´²é‡é»</h3>
          <ul class="point-list">
            <li class="point-item">ç„¡ç¨ç«‹æ³•å®šå­¤å…’å¸‚å ´ç¨å </li>
            <li class="point-item">æä¾›è©•å¯©è²»ç”¨æ¸›å…èˆ‡ç§‘å­¸è«®è©¢</li>
            <li class="point-item">å¯èˆ‡å„ªå…ˆ/é™ç¸®å¯©æŸ¥è·¯å¾‘æ­é…</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Comparison Table -->
    <section id="comparison-table" class="law-section">
      <h2 class="law-header">ä¸ƒã€å„å¸æ³•è½„å€æ¯”è¼ƒç¸½è¡¨ï¼ˆ2025 æ›´æ–°ï¼‰</h2>
      <div class="law-content">

        <div class="comparison-wrapper">
          <table class="comparison-table">
            <thead>
              <tr>
                <th>é …ç›®</th>
                <th>å°ç£</th>
                <th>ç¾åœ‹</th>
                <th>æ­ç›Ÿ</th>
                <th>æ—¥æœ¬</th>
                <th>åŠ æ‹¿å¤§</th>
                <th>æ¾³æ´²</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><strong>æ³•è¦ / åˆ¶åº¦</strong></td>
                <td>ç½•è¦‹ç–¾ç—…é˜²æ²»åŠè—¥ç‰©æ³•</td>
                <td>Orphan Drug Act</td>
                <td>Reg. 141/2000</td>
                <td>é›£ç—…æ³• + æŒ‡å®šé›£ç—…</td>
                <td>National Strategyï¼ˆæ”¿ç­–ï¼‰</td>
                <td>Orphan Drug Programï¼ˆæ”¿ç­–ï¼‰</td>
              </tr>
              <tr>
                <td><strong>å®šç¾©/é–€æª»</strong></td>
                <td>ç››è¡Œç‡ â‰¤1/10,000 + è³ªæ€§åˆ¤æº–</td>
                <td><200,000 æˆ–æˆæœ¬ä¸å¯å›æ”¶</td>
                <td>â‰¤5/10,000 + é¡¯è‘—æ•ˆç›Šåˆ¤æ–·</td>
                <td>å¤šè¦ç´ ï¼ˆå«æ‚£è€…ä½æ–¼ç´„ 0.1% äººå£ï¼‰</td>
                <td>ç„¡çµ±ä¸€å®šç¾©ï¼ˆåƒè€ƒåœ‹éš›ï¼‰</td>
                <td><5/10,000 æˆ–ç„¡å•†æ¥­å¯è¡Œæ€§</td>
              </tr>
              <tr>
                <td><strong>å¸‚å ´ç¨å </strong></td>
                <td>ç„¡ç¨ç«‹å­¤å…’æ’ä»–ï¼ˆä¸€èˆ¬è³‡æ–™ä¿è­·ï¼‰</td>
                <td>7 å¹´å­¤å…’æ’ä»–</td>
                <td>10 å¹´ï¼ˆå¯ç¸® / å…’ç§‘ 12 å¹´ï¼‰</td>
                <td>ç„¡å­¤å…’æ’ä»–åˆ¶åº¦</td>
                <td>ç„¡ï¼ˆä¸€èˆ¬ 8 å¹´ + å…’ç§‘ 6 æœˆï¼‰</td>
                <td>ç„¡ï¼ˆè²»ç”¨æ¸›å…ç‚ºä¸»ï¼‰</td>
              </tr>
              <tr>
                <td><strong>è³‡æ–™ / å…’ç§‘å»¶é•·</strong></td>
                <td>ä¾è—¥äº‹æ³•ä¸€èˆ¬è¦å‰‡</td>
                <td>Pediatric +6 æœˆ</td>
                <td>å…’ç§‘ +2 å¹´</td>
                <td>ç„¡å°ˆå±¬</td>
                <td>8 + 0.5 å¹´ï¼ˆå…’ç§‘ï¼‰</td>
                <td>ä¸€èˆ¬è¦å‰‡</td>
              </tr>
              <tr>
                <td><strong>ç¨…å‹™ / è²¡æ”¿æ¿€å‹µ</strong></td>
                <td>ç ”ç™¼æŠ•æŠµï¼ˆç”¢å‰µæ¢ä¾‹æ³›ç”¨ï¼‰</td>
                <td>ç ”ç™¼è‡¨åºŠæŠµå… 25%</td>
                <td>æœƒå“¡åœ‹è¦–æƒ…æ³</td>
                <td>ç ”ç©¶è£œåŠ©</td>
                <td>æœ‰é™ï¼ˆå°ˆæ¡ˆè³‡åŠ©ï¼‰</td>
                <td>ç„¡å°ˆå±¬ç¨…å‹™</td>
              </tr>
              <tr>
                <td><strong>è²»ç”¨æ¸›å…</strong></td>
                <td>å¯©æŸ¥è²»ç”¨æ¸›å…ï¼ˆéƒ¨åˆ†ï¼‰</td>
                <td>User Fee æ¸›å…</td>
                <td>EMA è²»ç”¨æ¸›å…</td>
                <td>æœ‰</td>
                <td>å€‹æ¡ˆ</td>
                <td>å¤§å¹…æ¸›å…</td>
              </tr>
              <tr>
                <td><strong>åŠ é€Ÿ / æ”¯æ´</strong></td>
                <td>å°ˆæ¡ˆå¯©æŸ¥ / é¢¨éšªåˆ†æ”¤</td>
                <td>Fast Track / BTD / Priority</td>
                <td>PRIME / Accelerated Assessment</td>
                <td>å€‹æ¡ˆå”èª¿</td>
                <td>å€‹æ¡ˆå„ªå…ˆ</td>
                <td>Priority / Provisional</td>
              </tr>
              <tr>
                <td><strong>çµ¦ä»˜æ¨¡å¼</strong></td>
                <td>NHI å¯©è­° + åŸºé‡‘è£œåŠ©</td>
                <td>ä¿éšªå¤šå…ƒï¼ˆç¼ºçµ±ä¸€ï¼‰</td>
                <td>æœƒå“¡åœ‹è‡ªè¨‚</td>
                <td>åŠ©æˆåˆ¶åº¦</td>
                <td>çœç´šå·®ç•°</td>
                <td>PBS HTA æ±ºç­–</td>
              </tr>
              <tr>
                <td><strong>é¢¨éšªåˆ†æ”¤ / æˆæœä»˜è²»</strong></td>
                <td>æ¼¸å¢ï¼ˆæˆæœ/ä¸Šé™ï¼‰</td>
                <td>å¯ï¼ˆç§å•†ä¿éšªå·®ç•°ï¼‰</td>
                <td>å¤šæ¡ MEA (Managed Entry)</td>
                <td>æœ‰é™</td>
                <td>æ¢ç´¢ä¸­</td>
                <td>å­˜åœ¨ï¼ˆHTA è«‡åˆ¤ï¼‰</td>
              </tr>
              <tr>
                <td><strong>æ‚£è€…ç™»éŒ„</strong></td>
                <td>æ¨å‹•æ•´åˆå¹³å°</td>
                <td>å¤šæ•£ç‹€ / NIH æ”¯æŒ</td>
                <td>Orphanet / EU ç¶²çµ¡</td>
                <td>æŒ‡å®šé›£ç—…ç™»éŒ„</td>
                <td>åˆ†æ•£ç ”ç©¶å°å‘</td>
                <td>å­¸æœƒ / å°ˆé¡Œ</td>
              </tr>
              <tr>
                <td><strong>æ”¿ç­–ç„¦é»ï¼ˆè¿‘æœŸï¼‰</strong></td>
                <td>é«˜é¡åŸºå› æ²»ç™‚è²¡å‹™æ°¸çºŒ</td>
                <td>åŠ é€Ÿç´°èƒ / åŸºå› ç™‚æ³•</td>
                <td>è©•ä¼°æ”¹é©èˆ‡é©æ‡‰æ€§å¯©æŸ¥</td>
                <td>æ“´å……ç™»éŒ„èˆ‡å…¬å¹³åŠ©æˆ</td>
                <td>çµ±ä¸€å¯åŠèˆ‡ HTA å”èª¿</td>
                <td>æˆæœ¬èˆ‡å¯©æŸ¥æ•ˆç‡å¹³è¡¡</td>
              </tr>
            </tbody>
          </table>
        </div>

        <div class="callout warn">
          <strong>è§£è®€æç¤ºï¼š</strong>ã€Œå¸‚å ´ç¨å ã€èˆ‡ã€Œè³‡æ–™ä¿è­·ã€æ³•å¾‹åŸºç¤ä¸åŒï¼›å°ç£è‘—é‡æ”¯ä»˜ä¿éšœèˆ‡é†«ç™‚å¯åŠï¼Œè€Œéæˆäºˆæ’ä»–éŠ·å”®æ¬Šã€‚
        </div>

      </div>
    </section>

    <!-- Sources -->
    <section id="sources" class="law-section">
      <h2 class="law-header">å…«ã€ä¾†æºèˆ‡åƒè€ƒé€£çµ</h2>
      <div class="law-content">

        <div class="source-links">
          <div class="source-card">
            <h4>å°ç£ ç½•è¦‹ç–¾ç—…æ³•</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020037" target="_blank">æ³•è¦åŸæ–‡</a>
          </div>
          <div class="source-card">
            <h4>è¡›ç¦éƒ¨ç½•è¦‹ç–¾ç—…å°ˆå€</h4>
            <a href="https://www.mohw.gov.tw" target="_blank">MOHW</a>
          </div>
          <div class="source-card">
            <h4>é£Ÿè—¥ç½²è—¥å“è³‡è¨Š</h4>
            <a href="https://www.fda.gov.tw" target="_blank">TFDA</a>
          </div>
          <div class="source-card">
            <h4>å¥ä¿ç½²çµ¦ä»˜è³‡æ–™</h4>
            <a href="https://www.nhi.gov.tw" target="_blank">NHI</a>
          </div>
          <div class="source-card">
            <h4>è¸å“å¥åº·ç¦åˆ©ææ¢ä¾‹</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0070026" target="_blank">æ³•æº</a>
          </div>
          <div class="source-card">
            <h4>Statute for Industrial Innovation</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=J0080032" target="_blank">ç”¢å‰µæ¢ä¾‹</a>
          </div>
          <div class="source-card">
            <h4>USA Orphan Drug Act</h4>
            <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360bb" target="_blank">21 U.S.C. 360bbâ€“dd</a>
          </div>
          <div class="source-card">
            <h4>FDA OOPD</h4>
            <a href="https://www.fda.gov/industry/developing-products-rare-diseases-conditions" target="_blank">FDA Guidance</a>
          </div>
          <div class="source-card">
            <h4>Tax Cuts and Jobs Act</h4>
            <a href="https://www.congress.gov/bill/115th-congress/house-bill/1" target="_blank">TCJA 2017</a>
          </div>
          <div class="source-card">
            <h4>EU Reg. 141/2000</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32000R0141" target="_blank">EUR-Lex</a>
          </div>
          <div class="source-card">
            <h4>EU Orphan Designation</h4>
            <a href="https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation" target="_blank">EMA</a>
          </div>
          <div class="source-card">
            <h4>Paediatric Reg. 1901/2006</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32006R1901" target="_blank">EUR-Lex</a>
          </div>
          <div class="source-card">
            <h4>æ—¥æœ¬ é›£ç—…æ³•</h4>
            <a href="https://elaws.e-gov.go.jp/document?lawid=426AC0000000050" target="_blank">e-Gov</a>
          </div>
          <div class="source-card">
            <h4>æ—¥æœ¬ æŒ‡å®šé›£ç—…</h4>
            <a href="https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000084783.html" target="_blank">åšåŠ´çœ</a>
          </div>
          <div class="source-card">
            <h4>åŠ æ‹¿å¤§ ç½•ç—…ç­–ç•¥</h4>
            <a href="https://www.canada.ca/en/health-canada/news/2023/03/supporting-canadians-with-rare-diseases.html" target="_blank">News Release 2023</a>
          </div>
          <div class="source-card">
            <h4>Canada Orphan Policy Background</h4>
            <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/initiatives/orphan-drugs.html" target="_blank">Health Canada</a>
          </div>
          <div class="source-card">
            <h4>Australia Orphan Guidance</h4>
            <a href="https://www.tga.gov.au/resources/resource/guidance/orphan-drug-designation" target="_blank">TGA</a>
          </div>
          <div class="source-card">
            <h4>Australia Fee Relief</h4>
            <a href="https://www.tga.gov.au/how-we-regulate/fees/orphan-drugs" target="_blank">TGA Fees</a>
          </div>
          <div class="source-card">
            <h4>Orphanet</h4>
            <a href="https://www.orpha.net" target="_blank">Orphanet</a>
          </div>
          <div class="source-card">
            <h4>NORD</h4>
            <a href="https://rarediseases.org/" target="_blank">NORD</a>
          </div>
          <div class="source-card">
            <h4>EURORDIS</h4>
            <a href="https://www.eurordis.org/" target="_blank">EURORDIS</a>
          </div>
        </div>

        <div class="footnotes">
          <h3>è¨»é‡‹ï¼ˆFootnotesï¼‰</h3>
          <ol>
            <li>å°ç£ç››è¡Œç‡é–€æª»ï¼šè¡Œæ”¿èªå®šåŸå‰‡ï¼ˆâ‰¤1/10,000ï¼‰ä»¥ç¢ºä¿è³‡æºç„¦é»ï¼›æ³•æ¢æˆæ¬Šä¸»ç®¡æ©Ÿé—œè¨‚å®šã€‚</li>
            <li>å°ç£æœªè¨­é¡ä¼¼ç¾/æ­å­¤å…’å¸‚å ´ç¨å ï¼›çµ¦ä»˜ä¿éšœèˆ‡è³‡æ–™ä¿è­·ç‚ºä¸åŒæ³•å¾‹å±¤æ¬¡ã€‚</li>
            <li>ç¾åœ‹ç¨…æ”¶æŠµå…ï¼š2017 å‰ 50%ï¼ŒTCJA å¾Œèª¿æ•´ç‚º 25% ä¸Šé™ã€‚</li>
            <li>æ—¥æœ¬ã€Œæ‚£è€…æ•¸ã€ç‚ºæ”¿ç­–åƒè€ƒéšå±¤ï¼ˆç´„ 0.1% äººå£ï¼‰ï¼Œéå”¯ä¸€ç¡¬æ€§æ•¸å€¼ã€‚</li>
            <li>åŠ æ‹¿å¤§ç„¡æ³•å®šçµ±ä¸€å®šç¾©ï¼›ç­–ç•¥ä»¥å”èª¿è³‡æºèˆ‡åŠ é€Ÿå¯åŠã€‚</li>
            <li>æ¾³æ´² 2017 æ”¹ç‰ˆå¾Œæ¡ç››è¡Œç‡ <5/10,000ï¼›å–æ¶ˆèˆŠæœ‰å€‹åˆ¥äººæ•¸è¡¨è¿°ã€‚</li>
            <li>æ­ç›Ÿé¡¯è‘—æ•ˆç›Šï¼ˆSignificant Benefitï¼‰å½±éŸ¿ç¶­æŒç¨å ä¹‹è³‡æ ¼ã€‚</li>
            <li>ã€Œé¢¨éšªåˆ†æ”¤ã€è¡“èªæ¶µè“‹æˆæœå‹èˆ‡æ”¯å‡ºä¸Šé™å‹ï¼Œå¤šåœ‹å°šåœ¨æ¼”åŒ–ã€‚</li>
          </ol>
        </div>

      </div>
    </section>

    <!-- Revision Log -->
    <section id="revision-log" class="revision-log">
      <h3>ä¹ã€ä¿®è¨‚ç´€éŒ„</h3>
      <ul>
        <li><strong>v1.2 (2025-09-09)ï¼š</strong>æ–°å¢å°ç£ç½®é ‚å°ˆç¯€ï¼ˆå®šç¾©ã€åŸºé‡‘ã€çµ¦ä»˜ã€æ¿€å‹µã€æ²»ç†ï¼‰ï¼›èª¿æ•´æ¯”è¼ƒè¡¨æ¬„ä½ï¼›è£œå……è²¡æºæ³•æºï¼›ç´°åŒ–é¢¨éšªåˆ†æ”¤èˆ‡ RWD æè¿°ã€‚</li>
        <li><strong>v1.1 (2025-09-09)ï¼š</strong>ä¿®æ­£ç¾æ—¥åŠ æ¾³éæ™‚èˆ‡éŒ¯èª¤æ•¸æ“šï¼›åŠ å…¥é¡¯è‘—æ•ˆç›Šã€å…’ç§‘å»¶é•·èªªæ˜ã€‚</li>
        <li><strong>v1.0 (åŸå§‹ç‰ˆæœ¬)ï¼š</strong>å­˜åœ¨å¤šé …éæ™‚æ•˜è¿°ï¼ˆç¾åœ‹ç¨…æ”¶ 50%ã€æ—¥æœ¬å–®ä¸€ 5 è¬äººã€æ¾³æ´² 2,000 äººç­‰ï¼‰ã€‚</li>
      </ul>
    </section>

    <!-- Disclaimer -->
    <section id="disclaimer" class="disclaimer">
      <strong>å…è²¬è²æ˜ï¼š</strong>æœ¬æ–‡ä»¶ä¾›æ”¿ç­–ç ”ç©¶èˆ‡æ•™è‚²åƒè€ƒï¼Œéæ³•å¾‹æ„è¦‹ã€‚å¯¦å‹™é©ç”¨è«‹ä»¥å„ä¸»ç®¡æ©Ÿé—œæœ€æ–°æ­£å¼å…¬å‘Šã€æ³•è¦åŸæ–‡èˆ‡å¯©è­°æŒ‡å¼•ç‚ºæº–ã€‚å°åŸºæ–¼æœ¬æ–‡æ‰€ç‚ºæ±ºç­–æ‰€ç”Ÿé¢¨éšªï¼Œè«‹å¦è¡Œå–å¾—å°ˆæ¥­æ³•è¦èˆ‡è—¥äº‹è«®è©¢ã€‚
    </section>

  </div>

  <button class="back-to-top" title="å›åˆ°é ‚éƒ¨" onclick="window.scrollTo({top:0,behavior:'smooth'})">â†‘</button>

  <script>
    const backBtn = document.querySelector('.back-to-top');
    window.addEventListener('scroll',() => {
      if(window.scrollY > 320){
        backBtn.style.display='block';
      } else {
        backBtn.style.display='none';
      }
    });
    document.querySelectorAll('a[href^="#"]').forEach(a=>{
      a.addEventListener('click',e=>{
        const id = a.getAttribute('href');
        if(id.length>1){
          e.preventDefault();
          const target=document.querySelector(id);
          if(target){ target.scrollIntoView({behavior:'smooth',block:'start'}); }
        }
      });
    });
  </script>
</body>
</html>
